Login / Signup

Body Height of MPS I and II Patients after Hematopoietic Stem Cell Transplantation: The Impact of Dermatan Sulphate.

Patryk LipińskiAgnieszka Różdżyńska-ŚwiątkowskaAgnieszka ŁugowskaJolanta MaruchaKatarzyna DrabkoAnna Tylki-Szymańska
Published in: Diagnostics (Basel, Switzerland) (2024)
Both MPS I and MPS II patients presented height gain after HSCT compared to the curves of untreated patients. The absence of dermatan sulphate after HSCT could lead to normal growth in bone length.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • prognostic factors
  • body mass index
  • hematopoietic stem cell